Methane-Oxidizing Activity Enhances Sulfamethoxazole Biotransformation in a Benthic Constructed Wetland Biomat.

Ammonia monooxygenase and analogous oxygenase enzymes contribute to pharmaceutical biotransformation in activated sludge. In this study, we hypothesized that methane monooxygenase can enhance pharmaceutical biotransformation within the benthic, diffuse periphytic sediments (i.e.

Scalable and customizable parallel flow-through reactors to quantify biological processes related to contaminant attenuation by photosynthetic wetland microbial mats.

Shallow, unit process open water wetlands harbor a benthic microbial mat capable of removing nutrients, pathogens, and pharmaceuticals at rates that rival or exceed those of more traditional systems. A deeper understanding of the treatment capabilities of this non-vegetated, nature-based system is currently hampered by experimentation limited to demonstration-scale field systems and static lab-based microcosms that integrate field-derived materials. This limits fundamental mechanistic knowledge, extrapolation to contaminants and concentrations not present at current field sites, operational optimization, and integration into holistic water treatment trains.

Pharmaceutical Biotransformation is Influenced by Photosynthesis and Microbial Nitrogen Cycling in a Benthic Wetland Biomat.

In shallow, open-water engineered wetlands, design parameters select for a photosynthetic microbial biomat capable of robust pharmaceutical biotransformation, yet the contributions of specific microbial processes remain unclear. Here, we combined genome-resolved metatranscriptomics and oxygen profiling of a field-scale biomat to inform laboratory inhibition microcosms amended with a suite of pharmaceuticals. Our analyses revealed a dynamic surficial layer harboring oxic-anoxic cycling and simultaneous photosynthetic, nitrifying, and denitrifying microbial transcription spanning nine bacterial phyla, with unbinned eukaryotic scaffolds suggesting a dominance of diatoms.